Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Former deputy prime minister, who left Meta this year, to be joined by Facebook-owner’s chief AI scientist ...

Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Experienced senior executive brings proven track record in financial strategy, operational excellence, and commercial execution ...

Hyderabad: Researchers who earlier identified a petroleum-eating bacterium in Nacharam have now decoded its entire genome, ...

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

Illumina (ILMN) has been grinding higher over the past month, even though the stock is still down over the past year, raising a simple question for investors: is this quiet rebound worth leaning into?

The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...

The universal features that define genomic regions acting as replication origins remain unclear. In this study, we mapped a set of origins in Trypanosoma brucei using stranded short nascent strand ...

Personalis Inc. company and executive profile by Barron's. View the latest PSNL company infomation and executive bios.

Single-cell sequencing provides unprecedented detail into cell-to-cell variability, uncovering key biological mechanisms in ...

The global genomics market is projected to expand by 15-17% by 2029. Key factors driving this growth include the increasing ...